A full service Contract Research Organization

Offices in the San Francisco Bay Area and Sydney, Australia

News

InClin Announces Office Relocation and Expansion in North Sydney, Australia

InClin Pty Ltd. is pleased to announce the opening of our new office in Australia; located at 25 Berry Street – No. 210 – North Sydney, Australia.

The new office demonstrates InClin’s continued commitment and investment in having a strong and visible presence in the region. InClin and InClin Pty Ltd have seen exciting growth in 2017 and having this expansion will only strengthen our company and allow us to continue that momentum into 2018.

“This new location signals the continued growth and success of our regional office in Australia,” said Taylor Kilfoil, Chief International Officer and Co-Founder of InClin. “Having an established office here in Sydney will enable us to attract and retain the highly skilled and specialized talent needed to support our continued growth and the expansion of the services we can offer to our clients placing studies in this region.”

With office locations in centralized biotech and drug development hubs such as Australia and California, InClin will continue to operate as a leading CRO in the world’s strongest biopharma markets.

About InClin

InClin is a full-service Contract Research Organization (CRO) with offices in the San Francisco Bay Area and Sydney, Australia. We are a single source provider of an integrated full suite of clinical development services from Phase 1 through Phase 4, including project management, clinical monitoring, site and contract management, vendor management, data management, biostatistics, programming, drug safety, medical monitoring, medical writing, QA inspection readiness, as well as strategic consulting services. For more information feel free visit our website or contact us at our email address below.

Read More

Dr. Charles Du Mond Joins InClin as Senior Vice President of Biometrics

InClin is pleased to announce that Charles Du Mond, PhD, has joined InClin as the Senior Vice President of Biometrics. In this role, Dr. Du Mond will review all InClin biometrics work products and be responsible for providing therapeutic area and technical expertise with respect to the development of the protocol, data collection, and conduct of the statistical analyses.

“We are thrilled to welcome Charles as our Senior Vice President of Biometrics,” said Arnold Wong, Chief Executive Officer of InClin. “His extensive experience and passion for innovative research and development makes him a great asset to the InClin team. I have no doubt that he will provide unparalleled and invaluable service to our customers in this role.”

Dr. Du Mond has 30+ years of experience working in the biotechnology, pharmaceutical, medical device, and CRO industries, providing study design, data management, clinical pharmacokinetics, statistical analysis, regulatory support, product development plans, and data safety monitoring boards.

Prior to InClin, Dr. Du Mond started his career at Syntex Research working in HIV/AIDS, antiviral products, and infectious disease. He went on to Liposome Technology (later renamed SEQUUS) and then co-founded Pacific Research Associates (PRA), which was subsequently acquired by ICON. Dr. Du Mond most recently served as Vice President of Biometrics at Relypsa. He received his MS and PhD in Statistics from The University of Iowa. He also has a BA in English and Mathematics/Computer Science from Central College in Pella, Iowa.

About InClin

InClin is a full-service Contract Research Organization (CRO) with offices in the San Francisco Bay Area and Sydney, Australia. We are a single source provider of an integrated full suite of clinical development services from Phase 1 through Phase 4, including project management, clinical monitoring, site and contract management, vendor management, data management, biostatistics, programming, drug safety, medical monitoring, medical writing, QA inspection readiness, as well as strategic consulting services. For more information feel free visit our website or contact us at our email address below.

Read More